Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) EBITDA Margin (2020 - 2025)

RxSight (RXST) has disclosed EBITDA Margin for 6 consecutive years, with 28.09% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 1244.0% year-over-year to 28.09%, compared with a TTM value of 29.04% through Dec 2025, down 954.0%, and an annual FY2025 reading of 29.04%, down 954.0% over the prior year.
  • EBITDA Margin was 28.09% for Q4 2025 at RxSight, up from 31.77% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 15.65% in Q4 2024 and bottomed at 275.27% in Q2 2021.
  • Average EBITDA Margin over 5 years is 93.96%, with a median of 61.25% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 20481bps in 2021, while the deepest fall reached -185391bps in 2021.
  • Year by year, EBITDA Margin stood at 186.84% in 2021, then skyrocketed by 48bps to 96.76% in 2022, then soared by 67bps to 31.92% in 2023, then skyrocketed by 51bps to 15.65% in 2024, then crashed by -80bps to 28.09% in 2025.
  • Business Quant data shows EBITDA Margin for RXST at 28.09% in Q4 2025, 31.77% in Q3 2025, and 35.43% in Q2 2025.